Sam Brusco, Associate Editor12.18.23
LUMA Vision, developer of a novel 4D cardiac imaging and navigation platform, has obtained $22 million in new financing.
The Series A3 financing added three new investors: Atlantic Bridge Growth Fund, Bayern Kapital, and an undisclosed multinational strategic investors. The funding round was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand.
The new funding adds to prior grants won from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million). LUMA said it will use the new funds to gain U.S. Food and Drug Administration (FDA) clearance, prepare for U.S. commercialization, and develop the next generations of its VERAFEYE platform for further clinical applications in cardiology and beyond.
LUMA’s VERAFEYE is an all-in-one 4D imaging and navigation platform with data-driven software applications designed for cardiology. The technology uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide high-resolution, 360-degree imagery of the beating heart and surrounding anatomy.
VERAFEYE can be used with other catheters or systems during cardiac surgery and, with multiple applications in one platform, can offer imaging guidance needed during cardiac surgery in real time, without needing X-ray or CT.
The company said its technology can help guide personalized therapy across atrial fibrillation, left atrial appendage closure and cardiac valve replacement.
“Physicians require accurate, real-time data at the point of care in order to effectively treat patients,” said LUMA Vision CEO Fionn Lahart. “Our goal with VERAFEYE is to provide the data and imaging physicians need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored for specific therapies in cardiology, we believe that VERAFEYE can be a bedrock of medical imaging for many years to come.”
He continued, “We are absolutely delighted to welcome to the company our new investors and gratified to secure the continued backing of our highly regarded existing investors. As a truly pan-European startup with offices in Dublin and Munich, we have grown our team significantly in the last three years and will continue to add world-class talent to help LUMA Vision achieve its goals.”
The Series A3 financing added three new investors: Atlantic Bridge Growth Fund, Bayern Kapital, and an undisclosed multinational strategic investors. The funding round was led by existing investors EQT Lifesciences, ABV Uni Fund and imec.xpand.
The new funding adds to prior grants won from the Irish government’s Disruptive Technologies Innovation Fund ($6 million) and the European Union’s EIC Accelerator ($3 million). LUMA said it will use the new funds to gain U.S. Food and Drug Administration (FDA) clearance, prepare for U.S. commercialization, and develop the next generations of its VERAFEYE platform for further clinical applications in cardiology and beyond.
LUMA’s VERAFEYE is an all-in-one 4D imaging and navigation platform with data-driven software applications designed for cardiology. The technology uses a proprietary catheter sensor combined with advanced digital imaging and deep learning to provide high-resolution, 360-degree imagery of the beating heart and surrounding anatomy.
VERAFEYE can be used with other catheters or systems during cardiac surgery and, with multiple applications in one platform, can offer imaging guidance needed during cardiac surgery in real time, without needing X-ray or CT.
The company said its technology can help guide personalized therapy across atrial fibrillation, left atrial appendage closure and cardiac valve replacement.
“Physicians require accurate, real-time data at the point of care in order to effectively treat patients,” said LUMA Vision CEO Fionn Lahart. “Our goal with VERAFEYE is to provide the data and imaging physicians need in one system to successfully treat as many of the conditions their patients face as possible. By developing a technology platform that can be tailored for specific therapies in cardiology, we believe that VERAFEYE can be a bedrock of medical imaging for many years to come.”
He continued, “We are absolutely delighted to welcome to the company our new investors and gratified to secure the continued backing of our highly regarded existing investors. As a truly pan-European startup with offices in Dublin and Munich, we have grown our team significantly in the last three years and will continue to add world-class talent to help LUMA Vision achieve its goals.”